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Abstract. 
The article explores the problem of urinary tract 
infection in pregnant women. It presents the 
statistical analysis of the frequency of different forms 
of urinary tract infection during pregnancy. Our data 
is compared to the statistics given by other national 
and international researchers. This research makes an 
attempt to compare two different treatment methods: 
using cefixime in dose 400mg 1 per day for 7 days 
and amoxicillin/clavulanate in dose 625mg 3 per day 
for 7 days. During the research conducted from 
September 2009 until June 2012 at State Healthcare 
Institution "Regional perinatal centre", 984 patients 
in I, II and III pregnancy trimesters were studied. In 
order to find out a potential influence of urinary tract 
microflora character for the intrauterine development, 
as well, as presence of infectious inflammatory 
diseases in neonates, a clinical observation of 
neonatal period for all the children born from the 
studied mothers was conducted.  A special attention 
was directed to appearance of different clinical 
infection forms. We find out that the pregnant women 
with the asymptomatic bacteriuria should be 
administered the antibiotics treatment in order to 
prevent clinically apparent urinary tract infections, to 
stop uropathogen flora growth and to limit their 
affect on fetus development. Microbiological urine 
testing for the patients in the course of the urinary 
tract infection may be employed as an informative 
test for evaluating the antibiotics treatment efficacy. 
Given a positive effect Amoxicilline/Clavulanate and 
Cefixime treatment may be recommended to the 
pregnant women with clinically apparent UTI and 
with asymptomatic bacteriuria 
Keywords: urinary tract infections, 
asymptomatic bacteriuria in the pregnant women, 
clinically apparent bacteriuria, acute cystitis, 
pielonephritis, antibacterial therapy, 
Amoxicillin/Clavulanate, Cefixime.  
Introduction. 
Urinary tract infections (UTI) are one of the 
most common ailments that require significant 
expenditures. These infections most often occur 
during pregnancy; according to a number of 
researchers  [1-7], their morbidity rate in the 
demographic ranges from 8 to 17 percent. 
Unfortunately, precise data on morbidity rate of 
various UTI during pregnancy and their impact on 
the patients’ quality of life in Russia may not be 
acquired. Although, such information is of crucial 
importance for carrying out an efficient treatment.  
There may be distinguished three major 
nosological entities of the UTI in the pregnant 
women: asymptomatic bacteriuria, acute cystitis and 
pielonephritis. The asymptomatic bacteriuria should 
be given a special attention in the system of 
infections, as it is attributed a constant relapse of its 
course with a low percentage of self-recovery, a high 
risk of complications development in mother, unborn 
child and neonate with a high probability of the 
infection symptomatic form onset in the urinary tract 
[8-14]. Presence of clinically apparent UTI form or of 
the asymptomatic bacteriuria in the mother subjects 
her to a significantly higher risk of premature 
delivery, preeclampsia, hypertension, hypohemia and 
postdelivery endometritis; while on the side of the 
unborn child, not rarely it turns out into 
complications, such as: arrested intrauterine 
development, fetal prematurity and congenital 
abnormalities development resulting in a higher risk 
of perinatal mortality [15, 16, 17].  
Despite the fact that currently, researches on 
infection process in the urinary tract of mother 
organism influencing pathologic behaviour in the 
fetoplacentar system are intensely conducted, yet the 
diagnostic and treatment algorithms, approaches to 
treatment and strategies of following the pregnant 
women in ambulatory and in-patient conditions have 
not been developed ultimately [9, 17]. Absence of a 
single established approach for bacteriological urine 
testing often leads to longer terms of diagnosing the 
asymptomatic bacteriuria and unsuitable treatment 
processes [18, 19, 20].  
Success in resolving many problems related to 
the urinary tract infections (UTI) and the bacteriuria 
in the pregnant women depends directly upon
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 conducting a rational etiotropic therapy, which 
represents one of integral parts in actual preventive 
treatment of potential complications provoked by 
such infections. At gestational UTI, choice of 
antibiotics in the most cases is made empirically 
based on local data of uropathogenes' sensitivity.  
Currently, for therapeutical purposes, 
Amoxicillin/Clavulanate is acknowledged as the most 
prospective in category of penicillins.  It is regarded 
as a medicine with a vast spectrum of effect, 
pertaining a bactericidal impact on gram-positive and 
gram-negative pathogens. This antibiotic is widely 
applied in urinary tract infection processes treatment 
during pregnancy, and is practically safe in relation to 
its effect on fetus [19, 21-24]. An alternative for the 
UTI treatment are cephalosporins, which surpass the 
penicillins in antimicrobial effect due to their 
resistivity against plasmid betalactamase. The 
cephalosporins are tolerated well, while allergic 
reactions that are typical for betalactame antibiotics 
occur less often, and have a much lighter course as 
compared to the penicillins. Like other antibiotics of 
the penicillin class, the cephalosporins are considered 
to be relatively safe for pregnant women and 
neonates. Until currently, however, there arise 
discussions regarding these or that UTI and 
bacteriuria treatment methods applied during 
pregnancy; an optimal and acceptable treatment 
regimen of these diseases in the pregnant women 
have not been determined finally [25, 26 , 27].  
Medicobiological and social significance of the 
problem regarding the urinary tract infections during 
pregnancy and necessity of treatment efficacy 
improvement have served as the grounds for 
conducting this research and studying 
pharmacological safety and efficiency of treating 
such diseases in the pregnant women.    
Purpose of the research 
Evaluation of morbidity rate and risk factors for 
the asymptomatic bacteriuria development in the 
pregnant women and elaborating antibacterial therapy 
approaches. 
Data and methods 
During the research conducted from September 
2009 until June 2012 at State Healthcare Institution 
"Regional perinatal centre", 984 patients in I, II and III 
pregnancy trimesters were studied.  At the first research 
stage, 984 pregnant women were subjected to clinical 
and laboratory screening study for urogenital infections, 
which included physical examination, clinical urine 
analysis and bacteriological urine testing (determining 
sensitivity to the antibiotics as well). All the patients 
were arranged into three groups according to duration of 
gestation (see Table 1). 
Table 1 
Description of the pregnant women subjected  
to screening study (n=984) 
Group description 
I Group 
(n=369) 
II Group 
(n=320) 
III Group 
(n=295) 
Age, years 29.5±3.6 27.8±2.8 28.6±3.1 
Women with 
 the UTI signs (%) 
31 (8.4%) 38 (11.9%) 49 (16.6%) 
Healthy  
women (%) 
338 (91.6%) 282 (88.1%) 246 (83.4%) 
 
I Group (369 persons – 37.5%) – are the women in 
5-14 weeks of gestation period, II Group (320 
persons – 32.5%) – women in 15-28 weeks of the 
period, III Group (295 persons – 30%) – women in 
29-40 weeks of the period. 
The age of the patients studied ranges from 18 to 
47 years and averagely constituted: 29.5±3.6 years – 
for the pregnant women in I Group; 27.8±2.3 – in II 
Group; 28.6±3.1 – in III Group. The prevailing 
women age was between 25-29 years (38.8%). 
The second research stage suggested a further 
study of 118 (12%) of the pregnant patients, who 
proved positive at the first stage in the bacteriological 
urine test taken twice at no less than 24-hour interval. 
A comparative efficacy and safety analysis of the 
urinary tract infections treatment performed with two 
different methods was conducted on these patients. 
The patients were divided into two groups:  the first 
group (group 1) included 25 women with clinical 
UTI signs, the second group (group 2) included 93 
patients without clinically apparent UTI. 
Subsequently, for a comparative study of various 
treatment regimens efficacy, the patients, who agreed 
to receive antibiotics therapy were randomised using 
random numbers method in two subgroups: subgroup 
A took Amoxicillin/Clavulanate in 625 mg dosage 
three times in 24 hours, their therapy lasted 7 days, 
subgroup B took Cefixime in 400 mg dosage once in 
24 hours with the therapy lasting 7 days as well. The 
first group (25 women) included: 1a subgroup – 14 
patients; 1b subgroup – 11 patients. The second 
group (93 pregnant women) included: 2a subgroup – 
35 patients; 2b subgroup – 35 patients. Out of 93 
patients without clinically apparent UTI, 23 rejected 
the antibiotics therapy, explaining that they had not 
any complaints and troubles regarding this case. They 
constituted a separate 2c group (Fig. 1). 
Examining all the patients, an anamnestic data 
analysis was carried out together with clinical, 
laboratory and microbiologocal in particular; 
ultrasound and statistical research methods were 
applied as well. 
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Figure 1. The Reseach procedure 
 
Urine culture study in aspect of asymptomatic 
bacteriuria screening was carried out for all patients 
of obstetric clinical hospital.  Screening along with 
the urine culture study aspect was also performed for 
ambulant patients of the clinical hospital, as well, as 
if bacteria were detected in the urine hypostasis, or 
the patients complained of dysuric manifestations 
and drawing pain in lumbus region. 
Before collecting the urine for culturing, the 
women received a detailed instruction on the urine 
collecting rules, following which conditioned 
reliability of microbiological test results and, 
ultimately, the treatment efficiency.    
The microbiological test and culturing of the 
medicine was performed in microbiological 
laboratory of the City hospital №6 in Kursk, Russia.  
Clinical efficacy of the treatment was evaluated 
on the basis of the pregnant women general state 
improvement with related data acquired using an 
interactive questionnaire of the University of 
Wisconsin Interstitial Cystitis Scale, 1998, which 
was modified by staff scientists of the Physical and 
Chemical Medicine Research Institute ("NII 
FKhM"). 
Table 2 
The evaluation of pharmacotherapy efficacy in points 
 Symptoms 0 points 1 point 
1. Intoxication symptoms: ailment, general muscular weakness No Present 
2. Complaints about pain: described as short-term, long-term, continuous; described as sharp, dull, 
colic-like; focalization: above pubic, perineal, in genitalia, with radiation to hip, in groin region, 
vulval lips, perineum; influence of body position on pain appearance, urination, physical load, 
medicine treatment     
No Present 
3. Dysuria: amount per 24 hours, urination intervals, incontience type, urinary urgency; presence 
of difficulties: initial retention, in 2 acts, sense of urinary bladder emptied incompletely 
No Present 
4. Pain manifestation focalization during urination in urethra, above pubic, behind pubic, in 
perineum, in genitalia region; pain sense occurrence at the beginning and at the end of urination  
No Present 
5. Urine quality alteration: colour, transparency – not altered, turbid, opalescent  No Present 
6. Pain and enlargement in peripheral nodes No Present 
7. Body temperature rise above 37 C° No Present 
8. Pain in lumbus region No Present 
9. Hyperhidrosis No Present 
10. Headache  No Present 
I stage- screening 
II stage 
984 women 
118 women (12%)  
with the UTI 
Group 2, n=93 
with asymptomatic 
bacteriuria  
Group 1, n=25  
with clinically apparent 
bacteriuria 
Group 1а 
n=14  
A/C therapy 
A/C therapy 
Group 1b, 
n=11 Cef. 
therapy 
Group 2а 
n=35 
 A/C therapy 
Group 2b 
n=35  
Cef. therapy 
Group 2c 
n=23 
untreated 
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Incidence of after-antibiotic-treatment side 
effects was evaluated with a questionnaire, which 
included a list of symptoms (Table 3). 
Table 3 
Incidence evaluation  
of after-pharmacotherapy side effects 
Symptoms Sign present 
Sign 
absent 
Headache, dizziness + - 
Itching, rash (allergic reactions) + - 
Loss of appetite  + - 
Pain in epigastrium + - 
Nausea, vomiting + - 
Bowel disorders (flux, 
opstipation) 
+ - 
Depression + - 
 
Laboratory efficacy was evaluated on the basis 
of microorganisms titer decrease acquired form 
results of culturing in 3-5 days and in 28 days after 
the antimicrobial treatment was finished. 
Statistical data processing was conducted using 
standard packages of Microsoft Excel 2007 and 
Statistica 10 software applications. Variants of 
qualitative and quantitative analyses were employed 
during the research.  
THE RESEARCH RESULTS AND 
DISCUSSION  
 The UTI morbidity rate relative to gestation 
duration of the women is given in  Figure 2. In I 
group, a positive culturing result was found in 32 
women (8.7% of cases), in II group – in 38 women 
(11.9%), in III group – in 48 women (16.6%).   
 
Figure 2. The UTI morbidity rate/gestation duration in the women 
 
The asymptomatic bacteriuria was diagnosed in 
case bacteria were detected in two urine samples 
collected consequently at 24-72 hour intervals in titer 
>10
5
 CFU/ml. According to the results of screening study 
performed on 984 women, the asymptomatic bacteriuria 
was found in 93 pregnant women (9.4%). The data 
acquired indicate a sufficiently high morbidity rate of the 
asymptomatic bacteriuria among the pregnant. Given 
this, almost every tenth woman at a mature term has an 
undiagnosed asymptomatic bacteriuria. 
Upon gestation term progression, a higher 
morbidity rate of the asymptomatic bacteriuria cases 
was observed (р<0.05), as compared to the total 
number of the UTI detected.  Thus, in group 1 the 
asymptomatic bacteriuria was found in 68.8% of 
cases (22 women), in group 2 – 78.9% (30 women), 
in group 3 – 85.4% (41 women).   
Authors consider as appropriate a tendency 
toward the UTI morbidity rate increase upon 
gestation progression. Factors that contribute to their 
development, such as the urinary tracts dilatation, the 
forward and upward urinary bladder disposition 
resulting from womb enlargement, increased renal 
blood flow, glomelural filtration and incomplete 
bladder emptying increase and aggravate upon the 
gestation progression. 
Clinically apparent urinary tract infection 
(according to anamnesis, general examination, tool 
and laboratory research data) was found in 25 women 
(2.5%). Acute cystitis was observed in 18 women 
(1.8%) and acute pielonephritis – in 7 women (0.7%). 
In two cases, the acute pielonephritis was combined 
with urinary stone disease. An etiological structure of 
asymptomatic bacteriuria germ was found in the 
pregnant women upon conducted microbiological 
study. Monoinfection proved to be prevailing in the 
following: one germ was cultured in 84 patients 
(90.3%), 2 and more – in 9 patients (9.7%). While in 
the patients with clinically apparent bacteriuria, a 
mixed infection was found in 36% of cases (9 
women) and the monoinfection – in 64% of the cases 
(16 women) (see Figure 3). 
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Figure 3. The structure of germs in the pregnant women with the asymptomatic and clinically apparent bacteriuria 
 
 
According to the data acquired from culturing, 
group of pregnant women with clinically apparent 
bacteriuria was revealed to have the following: 
esherichia coli was found in 11 women (44,0%), 
klebsiella pneumonia – in 2 women (8,0%), а 
staphylococcus spp. – in  2 women (8,0%), proteus 
mirabilis – in 1 woman (4%); a combination of two 
germs:  esherichia coli+klebsiella pneumonia was 
detected in 5 women (20%) and esherichia 
coli+staphylococcus spp – in 4 women (16%). 
According to the data acquired from urine 
culturing, in group of the pregnant women with the 
asymptomatic bacteriuria the following was revealed: 
esherichia coli was found in 72 women (77,4%), 
klebsiella pneumonia  – in 6 women (6,4%), а 
staphylococcus spp. – in 4 women (4,3%), proteus 
mirabilis – in 2 women (2,2%); a combination of two 
infectious agents: esherichia coli+klebsiella 
pneumonia was found in 6 women (6,5%),  
esherichia coli+staphylococcus spp – in 3 women 
(3,2%) (Fig. 5). 
 
 
 
Figure 4. Culturing results in patients with the clinically apparent bacteriuria (n=25)  
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Figure 5. Culturing results in patients with the asymptomatic bacteriuria (n=93) 
 
Clinical efficacy and safety of antibiotics 
treatment was evaluated using enquirers that listed 
clinical symptoms and side effects of the disease: 1 
group included 25 pregnant women with clinically 
apparent bacteriuria and 2 group included 93 women 
with asymptomatic bacteriuria. Description of the 
two groups is given in Table 4.  
Table 4 
Description of patients with the UTI (n=118) 
Group 
description 
1 group – clinically 
apparent UTI 
2 group – 
asymptomatic 
bacteriuria 
Women/ % 25/ 21.2% 93/ 78.8% 
Age, years 29.2±3.0 28.63.2 
Enquirer 
points 
8.5±0.8* 0 
Note: * р<0.05 – proven differences between the two 
groups 
 
Repeated clinical and laboratory study was 
performed after 3-5 days and 28 days after the 
therapy was finished. Subsequently, the patients in I 
and II groups were subjected to examination each 28 
days and until delivery.  
In order to analyse clinical manifestations of the 
urinary tract infections in the pregnant women during 
the research, anamnesis and disease analysis was 
performed, examinations were conducted, as well, as 
routine clinical and laboratory tests were carried out, 
such as clinical blood test, biochemical blood test, 
clinical urine analysis; urine culture and ultrasound 
scanning were executed for all the patients. 
Clinical examination of the pregnant women 
with clinically apparent bacteriuria revealed their 
most frequent complaints: ailment, general weakness 
and often urination in 100% of cases, gripes and 
discomfort at urination, subfebrile body temperature 
in 72% of cases. 
Analysis of pregnancy progress in the patients 
with the urinary tract infection revealed a high 
incidence of complications: 93 women (78.8%) had 
differently manifested swells; mild preeclampsia was 
observed in 47 women (39.8%); while severe 
gestosis was not found in the examined group. 
According to the data of the ultrasound scanning, the 
pregnant women with clinically apparent urinary 
tract infection revealed a proven disturbance 
incidence increase as compared to control group of 
practically healthy women. Thus, 12 patients 
(48.0%) were diagnosed with hydroamniosis, 6 
(24.0%) – with hypamnion, 5 (20.0%) – with 
presence of foreign matters in amniotic fluid, 3 
(12.0%) – with fetal growth retardation and chronical 
fetus hypoxia, 5 (20.0%) – with alteration in placenta 
maturity degree and thickness (p<0.05). At the same 
time, in the pregnant women with the asymptomatic 
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bacteriuria the following was observed: 
hydroamniosis found in 43 (46.2%) women, 
hypamnion found in 26 (28.0%), presence of foreign 
matter in amniotic fluid found in 11 (11.8%), fetal 
growth retardation found in 6 (6.5%), alteration in 
placenta maturity degree and thickness found in 10 
(10.8%), which also reliably proved to be higher as 
compared to the group of practically healthy women 
(р<0.05).  
During the research, a comparative study of 
medicine application efficacy, such as 
Amoxycilline/Clavulanate and Cefixime was 
conducted.   
After receiving an informed consent from the 
pregnant patients, those with clinically apparent 
bacteriuria in 1a subgroup were administered 625 mg 
of Amoxicilline/Clavulanate three times in 24 hours, 
for 7 days duration; in 1b subgroup – 400 mg of 
Cefixime daily, 7 days duration as well. In 2a 
subgroup, the pregnant patients with asymptomatic 
bacteriuria were administered 625 mg of 
Amoxicilline/Clavulanate three times in 24 hours for 
7 days; in 2b subgroup – 400 mg of Cefixime daily 
for 7 days, and 2c subgroup was a control group, 
which was not treated with the antibiotics. 
According to the data of control laboratory 
testing (performed 3-5 days after the antibiotics 
treatment was commenced), the efficacy of 
Amoxicilline/Clavulanate and Cefixime treatment for 
the pregnant patients group with clinical 
manifestation of the bacteriuria comprised 100%. 
Although, in single cases, 28 days after the therapy 
was over, microflora growth was observed after 
Amoxicilline/Clavulanate treatment in 7% of cases. 
In 3-5 days after taking Amoxicilline/Clavulanate, 
germ elimination was revealed in 100% of cases; in 
II group after Cefixime treatment, the germ 
elimination was revealed in 97% of cases, as urine 
culture results showed. In 28 days, microflora growth 
was found in urine culture of two pregnant women 
(5.7% of cases) treated with Cefixime and in one 
pregnant woman (2.8%) treated with 
Amoxicilline/Clavulanate. This may be related to 
that many bacteria species are able to live 
parasitically inside cells, showing affinity for various 
host cells, which is a facultative parasitism. For 
instance, Escherichia coli may parasitize in 
epithelium cells and in macrophagocytes, creating 
intracellular bacterial communities (IBC). Present 
fimbriae and microorganisms' enzymatic activity 
provides their penetration into cell or into 
intracellular space. Thus, a renewed bacteria growth 
may be related to difference between metabolic 
activity and growth speed of separate bacteria cells, 
as many antibiotics do not have effect on resting 
cells, as well, as because of a limited penetration of 
antimicrobial substances through biofilms. On the 
other hand, bacterial infection recurrence is 
conditioned by a particular microorganism's 
biological properties and host protection defects. 
 
Table 5 
The symtoms dynamics 28 days after the pregnant patients with clinically apparent bacteriuria  
were treated with the antibiotics 
Symptoms/ women (%) 
subgroup 1a 
before treatment 
subgroup 1a after 
Amox./Clav. 
treatment 
subgroup 1b 
before treatment 
subgroup 1b after 
Cefixime 
treatment 
General weakness 14 (100%) 2 (14.3±3.2%)↓* 11 (100%) 
0 
(0%)↓* 
Complaints for pain: above 
pubic, in genitalia and perineum 
14 (100%) 0 (0%)↓* 11 (100%) 1 (9.1±1.7%)↓* 
Dysuria: 14 (100%) 0 (0%)↓* 8 (72.7±11.6%) 0 (0%) 
Urine quality alteration: colour, 
transparency 
11 (78.6±11.4%) 0 (0%)↓* 5 (45.5±7.4%) 0 (0%) 
Pain manifestations at urination 10 (71.4±10.8%) 0 (0%)↓* 8 (72.7±11.6%) 
0 
(0%)↓* 
Pain and enlargement of 
peripheral nodes 
6 (42.8±9.1%) 0 (0%)↓* 5 (45.5±7.4%) 
0 
(0%)↓* 
Body temperature rise above 
37C° 
10 (71.4±10.8%) 0 (0%)↓* 8 (72.7±11.6%) 
0 
(0%)↓* 
Pain in lumbus region 7 (50.0±9.4%) 0 (0%)↓* 7 (63.6±10.4%) 
0 
(0%)↓* 
Hyperhidrosis 9 (64.3±10.2%) 1 (7.1±1.5%)↓* 9 (81.8±12.7%) 1 (9.1±1.7%)↓* 
Headache 9 (64.3±10.2%) 0 (0%)↓* 9 (81.8±12.7%) 
0 
(0%)↓* 
Note: * р<0,05 – are the proven differences from the indicator before the treatment,            
alteration of the indicator relative to initial value
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In 2c subgroup (n=23), the pregnant patients 
with asymptomatic bacteriuria, who were not treated 
with antimicrobial medicine; 11 (47.8%) women 
were observed to adjoin clinical UTI in 2-13 weeks 
(6.1±0.8 on average), which was accompanied by 
germ titer increase. As for clinical symptoms, a more 
often urination (43.5%) with discomfort and itching 
or pain at the urination (39.1%) was observed. In 12 
pregnant women (52.2%), the germ titer was found to 
increase: in 7 women (30.4%) with 100000 to 1 
million CFU, and in 5 (21.7%) women with 100000 
to 500000 CFU without adjoined clinical UTI.  
Symptoms related to infective inflammatory 
process in the pregnant women with clinical 
presentations of the bacteriuria showed a positive 
tendency for decrease after 3 days of antimicrobial 
medicine treatment.  
So, in more than 80% of cases treated with the 
antimicrobial medicine, 1a and 1b subgroup patients 
were observed to have a rapid elimination of general 
weakness and hyperhydrosis, while painfulness and 
nodes’ enlargement was observed to decrease in 50% 
of the patients.    
After 28 days of antimicrobial medicine 
treatment, the patients in both subgroups witnessed a 
significant improvement of their general state, in 
particular, none of the pregnant women complained 
for dysuric disorders or nodes enlargement and none 
was found to have a body temperature rise.   
Although, no proven differences in the studied 
medicine efficacy were found, p>0.05 (see Table 6).
Table 6 
The comparative description of 
Amoxicilline/Clavulanate and Cefixime efficacy  
for treating clinically apparent bacteriuria  
in the pregnant patients. 
Description groups 
subgroup 1a  
n=14 
subgroup 1b 
n=11 
Women/ % 14/ 56% 11/ 44% 
Age, years 29.1±2.8 28.8±3.0 
Enquirer points before 
treatment 
8.65±0.62 8.37±0.76 
Enquirer points 28 days after 
treatment 
0.78±0.05↓* 0.65±0.08↓* 
Note: * р<0,05 – are the proven differences from the 
indicator before the treatment, ↑↓ – alteration of the 
indicator relative to initial value. 
 
In the pregnant women group with clinical 
presentations of the UTI, 7 patients showed 
indicators improvement 28 days after the antibiotics 
therapy, according to ultrasound scanning results.  
Thus, disturbance incidence in this group decreased 
from 88.0% to 60.0%.   
After the patients with the asymptomatic UTI 
were treated, percentage of those with disorders 
decreased from 72.9% to 56.7%. In the group of 
pregnant women with asymptomatic UTI, who were 
not subjected to the treatment, pathological signs 
incidence was observed to increase from 69.6% to 
78.3% after 30 days, which was revealed by the 
ultrasound scanning.  
Table 7 
The morbidity rate of the UTI signs in the pregnant women revealed by the ultrasound scanning 
Ultrasound scanned symptoms/ 
groups 
Clinically manifested 
bacteriuria 
(treated patients) 
n=25 
Asymptomatic bacteriuria, 
(treated patients) 
n=70 
Asymptomatic 
bacteriuria (untreated 
patients) 
n=23 
Before 
antibio treat. 
After antibio 
treat. 
Before 
antibio treat. 
After antibio 
treat. 
1st 
ultrasound 
scan 
2nd 
ultrasound 
scan 
Hydroamniosis 12 9 31 24 12 14 
Hypamnion  6 5 20 13 6 5 
Foreign matters in amniotic fluid   5 4 7 4 4 5 
Fetal growth retardation  3 2 4 4 2 2 
Alteration of placenta thickness 
and maturity degree   
5 4 6 4 4 6 
 
As seen in Table 7, the disorders incidence for 
the both groups, which were subjected to the 
antibiotics treatment, showed a tendency toward 
decline, while in the control study group without the 
medicine treatment, incidence rose after 28 days. 
An important fact is that none of the pregnant 
women witnessed side effects for the antibiotic 
treatment, which were related to the medicine taking, 
demanding the medicine administration cancellation.  
In order to find out a potential influence of 
urinary tract microflora character for the intrauterine 
development, as well, as presence of infectious 
inflammatory diseases in neonates, a clinical 
observation of neonatal period for all the children 
born from the studied mothers was conducted.  A 
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special attention was directed to appearance of 
different clinical infection forms. A pathological loss 
of initial body weight and umbilical wound state, 
which is not a typical infection manifestation, were 
also considered.    
Table 8 
The complications upon delivery   
Delivery outcome and neonate 
state 
Group 1a 
n=14 
Group 1b 
n=11 
Group 2a 
n=35 
Group 2b 
n=35 
Group 2c 
n=23 
Small-for-gestational-age fetus 0 0 1 
(2.9±0.8%) 
1 
(2.9±0.8%) 
3 
(13.0±2.6%)* 
Neonate condition less than 7 
on Apgar scale 
2 
(14.3±2.8%) 
1 
(9.1±2.1%) 
4  
(11.4±2.3%) 
3 
(8.6±2.0%) 
3  
(13.0±2.6%) 
 
Premature  delivery 
1 
(7.1±1.9%) 
1 
(9.0±2.1%) 
1  
(2.9±0.8%) 
1 
(2.9±0.8%) 
4  
(17.4±2.9%)* 
 
Preterm amniorrhea 
1  
(7.1±1.9%) 
0 1  
(2.9±0.8%) 
2 
(5.7±0.9%) 
3  
(13.0±2.6%) 
Inherent vesicopustulosis 0 0 0 1 
(2.9±0.8%) 
2 
(8.7±2.0%) 
Conjuctivitis 
  
0 0 1 
(2.9±0.8%) 
0 1 
(4.3±0.9%) 
Umbilical wound delayed 
healing 
0 0 0 0 2 
(8.7±2.0%)* 
Pneumonia 0 0 0 0 0 
Sepsis, meningitis, neonate 
deaths 
0 0 0 0 0 
Note: * р<0,05 – are the proven differences from prior-to-treatment indicators  
 
Small-for-gestational-age fetus was evaluated on 
the basis of weight and height indicators, that is, if a 
neonate’s body weight to height ratio was below 60. 
In is worth noting, that the small-for-gestational-age 
fetus was proven to be higher (p<0.05) in untreated 
2c group, as compared to the other groups. 
Upon delivery, all the children's state was 
evaluated according to the Apgar scale with point 
range 1-10 at 1st and at 5th minutes of their lives. 
The state of the most neonates was evaluated at 8-9 
points. Number of the children born with less than 7 
points ranged from 8.6% to 14.3%, although, proven 
differences in the studied groups were not found. 
Among clinical infection manifestations found in the 
children were: inherent vesicopustulosis found in 
three cases, umbilical wound delayed healing, as 
well, as conjunctivitis found in two cases.  No cases 
of pneumonia, sepsis, meningitis and neonate deaths 
were registered in the studied groups. 
 Among the studied groups of pregnant women, 
proven differences in these infectious complications 
were detected in cases with a delayed healing of the 
umbilical wound (8.7%) and premature delivery 
(17.4%).  
The data acquired provides a high degree of 
proven ground to relate microorganisms’ persistency 
in lower urinary tracts to the neonates born with 
small-for-gestational-age fetus signs, 
morphofunctional dismaturity, umbilical wound 
delayed healing and tendency to premature delivery 
in cases with bacteriuria.   
Discussion of results 
In conclusion, a high therapeutic efficacy of 
Amoxicilline/Clavulanate and Cefixime, and a high 
tolerance to the medicine in the pregnant women, as 
well, as absence of their effect on fetus state provide 
grounds for recommending a 7-day treatment 
programme of Amoxicilline/Clavulanate in 625 mg 
dosage, three times in 24 hours, as an efficient 
method of the urinary tract infection treatment during 
II and III trimesters of pregnancy. Along with a low 
possibility of side effects and complications, and in 
case of the patients' intolerance for Amoxicilline/ 
Clavulanate, a 7-day treatment with 400 mg Cefixime 
once a day, orally, may be recommended as an 
alternative for treating the urinary tract infections in 
the pregnant women during II and III trimesters. 
In the research conducted, upon comparison of 
Amoxicilline/Clavulanate and Cefixime application 
for treating the pregnant women with a clinically 
apparent and asymptomatic bacteriuria, both 
medicines were found to be highly efficient, and the 
recovery rate was 93% and 97% correspondingly, 
which agrees well with the results of the researches 
conducted earlier. It should be noted that the acquired 
treatment tolerance data definitely proved these two 
medicines to be comparable in side effects incidence. 
Having calculated cost/efficiency indicators, the 
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following was revealed:  for Amoxiclav it was 525 
rubles, and 859 rubles for Suprax, which indicates 
that the first medicine is more cost-effective. 
In total, therefore, combination of a high 
therapeutic efficacy, good tolerance and safety of 
Amoxicilline/Clavulanate and Cefixime brings us to 
conclusion that they may be reasonably applied for 
clinically apparent and asymptomatic bacteriuria 
treatment during the three pregnancy trimesters.  
We believe that the results of the conducted 
research we have achieved our goal. Data from our 
study coincide with those in the foreign press, and 
will complement the data published in Russian 
sources. 
Conclusion 
1. According to results of sreening study 
performed on 984 pregnant women, the urinary tract 
infection morbidity rate was 12% (118 women); 
bacteriuria morbidity rate was found to increase 
along with gestation progression from 8.4%  
(31 women) in 5-14 pregnancy weeks and 11.9% (38 
women) in 15-28 weeks to 16.6% (48 women) in  
29-40 weeks.  
2. The clinically apparent urinary tract infection 
(according to anamnesis, general examination, tool 
and laboratory research data) was found in 25 women 
(2.5%). Acute cystitis was observed in 18 women 
(1.8%) and acute pielonephritis in 7 women (0.7%). 
The asymptomatic bacteriuria was detected in 93 
pregnant women (9.4%).  
3. The monoinfection prevailed in pregnant 
women with the asymptomatic bacteriuria: 90.3% of 
cases (84 women); 2 and more  uropathogenes were 
revealed in 9.7% of cases (9 women). While in the 
patients with clinically apparent bacteriuria, the 
monoinfection was found in 64% of cases (16 
women) and the mixed infection was found in 36% of 
cases.  The uropathogenes’ structure of the urinary 
tract infections in the pregnant women comprises the 
following microorganisms: Escherichia coli – 79.1%,  
Klebsiella pneumoniae – 8.3 %, Proteus mirabilis – 
6.7%, Staphylococcus spp. – 5.9%. 
4. The antibacterial therapy provides a sustained 
and apparent clinical-and-laboratory tested effect. 
The group of patients, who were subjected to 
antibacterial therapy revealed a statistically 
significant decrease of the urinary tract infection 
symptoms, a lower rate of positive culturing in 93-
97% of cases (p<0.05) and absence of significant side 
effects from the antibiotics treatment (p>0.05).  
In case, the antibiotic treatment was not conducted at 
the asymptomatic bacteriuria, clinical urinary tract 
infections were observed to adjoin in 47.8% of cases, 
while the germ titer increased; an isolated germ titer 
increase in the urine was observed in 52.2% of cases.  
5. The results of performed clinical and 
laboratory study did not reveal proven differences in 
efficacy and safety of the two antimicrobial 
medicines (Amoxicilline/Clavulanate and Cefixime), 
(p>0.05).  Thus, the antimicrobial medicines may be 
recommended to the pregnant women with the 
urinary tract infections and with the asymptomatic 
bacteriuria for the scope of germ elimination.  
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